From Science to Execution

Cryoport, Inc. (CYRX) analyzes that the valuation criteria for cell and gene therapy (CGT) companies are expanding from clinical data to manufacturing and supply chain execution. In the continuous process from patient-specific raw material collection, cryogenic transportation, storage, manufacturing, and administration, even a single temperature deviation or handover error can lead to treatment failure and revenue loss. Therefore, an investment framework that verifies quality control (CMC), scalability, and capital efficiency together is becoming more important than the previous approach of prematurely reflecting commercial value based solely on clinical success.

Cryoport's Strategic Position

Cryoport combines its Cryoportal digital logistics management, Chain of Compliance quality system, and global supply chain centers to support stages from preclinical to commercial. As of the end of 2025, it supported 760 clinical trials, 86 of which were Phase 3. Revenue from 20 commercial CGT products reached USD 33.4 million, a 28.6% increase from the previous year. Total revenue also rose to USD 176.2 million, a 12.4% increase, demonstrating a structure where repeat revenue expands as clinical pipelines convert into approvals and commercial volumes. However, for higher network ROI, developers must be encouraged to outsource integrated supply chains rather than build their own facilities.

Supply Chain Value Demonstrated by Approved Products

A representative case is Novartis (NVS)'s Kymriah (tisagenlecleucel), an autologous CAR-T that targets CD19 by modifying patient T cells. It was approved after Phase 2 ELIANA. The FDA Oncologic Drugs Advisory Committee recommended it 10-0 on July 12, 2017, and the FDA approved it on August 30, 2017, followed by the EMA on August 23, 2018, and Japan on March 26, 2019. In the same CD19 market, Gilead Sciences (GILD)'s Yescarta (axicabtagene ciloleucel), Bristol Myers Squibb (BMY)'s Breyanzi (lisocabtagene maraleucel), and Autolus Therapeutics (AUTL)'s Aucatzyl (obecabtagene autoleucel) are competing. Factors such as efficacy differences, manufacturing success rates, vein-to-vein time, and the speed of treatment center expansion influence market share.

Market and Investment Considerations

The global CGT market is estimated to reach USD 12.21 billion by 2025, with rising demand for logistics, storage, and quality control as high-cost, one-time therapies increase. In-house facilities can create fixed cost burdens if demand grows slower than expected, but Cryoport's integrated outsourcing model allows developers to adjust costs according to clinical stage and regional demand. Meanwhile, companies like Thermo Fisher Scientific (TMO), Novo Holdings (which acquired Catalent), and DHL Group are expanding their biologics logistics and manufacturing infrastructure, intensifying service differentiation competition. The key to investment decisions is not the number of supported clinical trials, but the conversion rate of Phase 3 programs into approvals and the growth rate of commercial product revenue.